INTRODUCING TRIALS IN
SINGAPORE AND HONG KONG While Icon’s doctors in Singapore have long been participating in clinical trials, these were operated using an outsource model. With a global approach to cancer care, in 2021 Icon Group prioritised the evolution of research in Singapore and Hong Kong with the introduction of a dedicated clinical trials division including a new Director of Clinical Trials, Joanne Chio, to lead the ASEAN trials portfolio. Alongside experienced clinical research coordinators and dedicated oncologists, 2021 marked a year of establishing solid foundations to bring an in-depth level of trials to the region.
HIGHLIGHTS • In May 2021 an Icon Singapore Research Committee
months, including Icon’s first paediatric oncology trial
with committee members including Dr Tan Yew Oo,
(Y-mAbs 203) and the first in the private sector for
Dr Karmen Wong, Dr Patricia Kho, Dr Lee Guek Eng,
neuroblastoma. Principal Investigator: Dr LeLe Aung
Dr Robert Lim, Dr Daniel Chan and Dr LeLe Aung. This committee has helped to enhance research collaboration across Icon sites and will continue to grow Icon’s regional reach across the ASEAN region, working closely with shared partners to continue to
• G rew from one to five Principal Investigators, totalling 67% of Singapore doctors participating in clinical trials as either Principal Investigators or Co-Investigators • Set-up foundations for an extensive trial portfolio in
improve access to clinical trials. It will also increase
Hong Kong. Partnered with BioAtla who have selected
collaboration with Icon’s mature research team in
Icon Cancer Centre Hong Kong as a site to conduct a
Australia and leverage established industry partners
leading immunotherapy lung cancer trial.
and seek international opportunities • A dded two new trial sites in Singapore. Icon Cancer Centre Farrer Park has been designated as trial headquarters with two new satellite sites established at Icon Cancer Centre Gleneagles and Mount Alvernia
38
• L aunched ten clinical trials across the span of nine
was established, chaired by Dr Hsieh Wen-Son and
ICON ANNUAL RESEARCH REPORT 2021
